Key regions: France, Europe, United Kingdom, Brazil, India
The Oncology Drugs market in Australia & Oceania has been steadily growing in recent years, driven by a combination of customer preferences, local special circumstances, and underlying macroeconomic factors.
Customer preferences: One of the key customer preferences in the Oncology Drugs market in Australia & Oceania is for treatments that are targeted and personalized. Patients are increasingly looking for therapies that are tailored to their individual needs and genetic makeup, and drug manufacturers are responding by developing more specialized treatments. Another important customer preference is for drugs that have fewer side effects and are easier to administer, such as oral medications.
Trends in the market: One trend in the Oncology Drugs market in Australia & Oceania is the increasing use of immunotherapy. This approach uses the body's own immune system to fight cancer, and has shown promising results in a number of different types of cancer. Another trend is the development of combination therapies, where multiple drugs are used together to target different aspects of the cancer. This approach has the potential to be more effective than using a single drug alone.
Local special circumstances: One of the local special circumstances affecting the Oncology Drugs market in Australia & Oceania is the high incidence of skin cancer in the region. Australia has one of the highest rates of skin cancer in the world, and this has led to a focus on developing treatments for this type of cancer. Another special circumstance is the relatively small population of the region, which can make it challenging for drug manufacturers to justify the high cost of developing new treatments.
Underlying macroeconomic factors: The Oncology Drugs market in Australia & Oceania is also influenced by a number of underlying macroeconomic factors. One of these is the aging population, which is driving an increase in the incidence of cancer. Another factor is the growing demand for healthcare services in the region, which is leading to increased investment in the sector. Finally, the region's strong intellectual property laws and regulatory environment are attracting investment from drug manufacturers looking to develop new treatments.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
